CBClaus R. Bartram

Claus R. Bartram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claus R. Bartram has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acute Lymphoblastic Leukemia in Children

    by Claus R. Bartram, André Schrauder, Rolf Köhler, Martin Schrappe

    Acute lymphoblastic leukemia (ALL) is the commonest malignancy in children (aged 1?18 years), accounting for almost 30% of all cancers in this age group. In Germany, every year four in every 100 000 children aged up to 15 develop ALL (Box). Almost...


  • Open Access

    BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study

    by Bernd Frank, Kari Hemminki, Alfons Meindl, Barbara Wappenschmidt, Christian Sutter, Marion Kiechle, Peter Bugert, Rita K Schmutzler, Claus R Bartram, Barbara Burwinkel

    Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC). We investigated the effect of BRIP1 -64G>A and Pro919Ser on familial BC risk by means of TaqMan allelic discrimination, analysing BRCA1/BRCA2 mutation-negative index patients of 571 German BC families and 712 control individuals. No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G>A and Pro919Ser were observed. We found no effect of the putatively functional BRIP1 variants -64G>A and Pro919Ser on the risk of familial BC.


  • Open Access

    Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study

    by Barbara Burwinkel, Kalai S Shanmugam, Kari Hemminki, Alfons Meindl, Rita K Schmutzler, Christian Sutter, Barbara Wappenschmidt, Marion Kiechle, Claus R Bartram, Bernd Frank

    The transcription factor 7-like 2 (TCF7L2) is a critical component of the Wnt/β-catenin pathway. Aberrant TCF7L2 expression modifies Wnt signaling and mediates oncogenic effects through the upregulation of c-MYC and cyclin D. Genetic alterations in TCF7L2 may therefore affect cancer risk. Recently, TCF7L2 variants, including the microsatellite marker DG10S478 and the nearly perfectly linked SNP rs12233372, were identified to associate with type 2 diabetes. We investigated the effect of the TCF7L2 rs12255372 variant on familial breast cancer (BC) risk by means of TaqMan allelic discrimination, analyzing BRCA1/2 mutation-negative index patients of 592 German BC families and 735 control individuals. The T allele of rs12255372 showed an association with borderline significance (OR = 1.19, 95% C.I. = 1.01-1.42, P = 0.04), and the Cochran-Armitage test for trend revealed an allele dose-dependent association of rs12255372 with BC risk (P trend = 0.04). Our results suggest a possible influence of TCF7L2 rs12255372 on the risk of familial BC.